Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.

ABSTRACT:

Importance

Palliative thoracic radiotherapy (RT) can alleviate local symptoms associated with advanced non-small cell lung cancer (NSCLC), but esophagitis is a common treatment-related adverse event. Whether esophageal-sparing intensity-modulated RT (ES-IMRT) achieves a clinically relevant reduction in esophageal symptoms remains unclear.

Objective

To examine whether ES-IMRT achieves a clinically relevant reduction in esophageal symptoms compared with standard RT.

Design, setting, and participants

Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE) is a multicenter phase 3 randomized clinical trial that enrolled patients between June 24, 2016, and March 6, 2019. Data analysis was conducted from January 23, 2020

SUBMITTER: Louie AV 

PROVIDER: S-EPMC8874872 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature